Arix Bioscience PLC (ARIX) Portfolio company Ensoma announces
closing of Series B Extension 16-May-2023 / 16:36 GMT/BST
-----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Portfolio company Ensoma announces closing of Series B
Extension
LONDON, 16 May 2023: Arix Bioscience plc ("Arix" or the
"Company") (LSE: ARIX), a transatlantic venture capital company
focused on investing in breakthrough biotechnology companies, notes
that its portfolio company Ensoma has closed an extension of its
Series B financing, raising a further USD50 million to bring the
total round to USD135 million.
The USD50 million extension round was raised by new investors
Kite, a Gilead Company, Bioluminescence Ventures, Delos Capital,
and by existing investor SymBiosis.
Arix co-led the initial Series B financing in January 2023,
committing USD9 million to the round alongside co-lead investor,
5AM Ventures, as well as Alexandria Venture Investments, the Bill
& Melinda Gates Foundation, Catalio Capital Management,
Cormorant Asset Management, F-Prime Capital, Fred Hutchinson Cancer
Center, Mirae Asset, Qatar Investment Authority (QIA), Solasta
Ventures, Takeda Ventures Inc., and Viking Global Investors.
Following the Series B extension, Arix's percentage holding has
been diluted from 7.6% to 6.1%. The holding value remains
unchanged.
Robert Lyne, CEO of Arix Bioscience, said: "We are very pleased
to see Ensoma being supported by a syndicate of top tier investors,
including that of big pharma, which is a testament to the strength
of the business. The funds raised will enable the company to
advance the development of its in vivo engineered cell therapy
platform and accelerate its pipeline of genomic medicines for
immuno-oncology and other applications. We look forward to
continuing our support to Ensoma as it seeks to bring a potentially
breakthrough therapy to clinic."
The announcement can be accessed on Ensoma's website at:
https://ensoma.com/ and the full text of the announcement from the
company is contained below.
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
ir@arixbioscience.com
Powerscourt Group
Sarah MacLeod, Ibrahim Khalil, Nick Johnson
+44 (0)20 7250 1446
arix@powerscourt-group.com
About Arix Bioscience plc
Arix Bioscience plc is a transatlantic venture capital company
focused on investing in breakthrough biotechnology companies around
cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the
capital, expertise, and networks to help accelerate their ideas
into important new treatments for patients. As a listed company, we
are able to bring this exciting growth phase of our industry to a
broader range of investors. www.arixbioscience.com
Ensoma Closes Series B Extension, Bringing Total Round to USD135
Million
Previously announced USD85 million financing extended by USD50
million
BOSTON, May 16, 2023 - Ensoma, a genomic medicines company
developing one-time, in vivo treatments that precisely engineer any
cell of the hematopoietic system, today announced the closing of an
extension of its Series B financing by USD50 million, bringing the
total size of the funding round to USD135 million. The USD50
million was contributed by new investors Kite, a Gilead Company
(Nasdaq: GILD), Bioluminescence Ventures and Delos Capital and by
existing investor SymBiosis. These investors joined a syndicate of
leading healthcare funds to advance the development of Ensoma's
EngeniousT in vivo engineered cell therapy platform and pipeline of
genomic medicines for immuno-oncology, genetic disease and other
therapeutic applications.
"Ensoma is creating a new generation of smart immune cell
medicines by harnessing the
concerted power of multiple immune cell types," said Emile
Nuwaysir, Ph.D., chief executive officer of Ensoma. "There are
millions of patients that need better answers. With this financing,
we are well positioned to bring our breakthrough therapies to the
clinic."
In connection with the extension financing, Kouki Harasaki,
Ph.D., managing partner at
Bioluminescence Ventures, will join Ensoma's Board of Directors.
Dr. Harasaki commented, "Ensoma's Engenious platform brings
together delivery and engineering capabilities to unlock the full
promise of in vivo multiplexed therapies. We are very excited about
working with the Ensoma team to make this a reality."
Other investors in the Series B included 5AM Ventures, Arix
Bioscience, Alexandria Venture
Investments, the Bill & Melinda Gates Foundation, Catalio
Capital Management, Cormorant
Asset Management, F-Prime Capital, Fred Hutchinson Cancer
Center, Mirae Asset, Qatar
Investment Authority (QIA), Solasta Ventures, Takeda Ventures,
Inc., and Viking Global
Investors.
About Ensoma
Ensoma believes the future of medicine lies within us. The
company is poised to create a new therapeutic category addressing
diseases that impact millions around the globe, such as cancer and
autoimmunity. The EngeniousT platform can uniquely address these
disorders by leveraging world-class technologies for in vivo
delivery and genome engineering. The ability to target and
reprogram both immune cells and self-renewing hematopoietic stem
cells will create multicellular and multigenic medicines that solve
potency and durability challenges limiting current approaches.
Ensoma also has the potential to leapfrog therapies in well
validated indications such as hemoglobinopathies and dramatically
expand patient eligibility through its portable in vivo solutions.
Ensoma is supported by top-tier investors, strategic partners and a
passionate team committed to a bold, global vision for genomic
medicine. For more information, please visit www.ensoma.com.
END
-----------------------------------------------------------------------------------------------------------------------
Dissemination of a Regulatory Announcement, transmitted by EQS
Group. The issuer is solely responsible for the content of this
announcement.
-----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071
Category Code: PFU
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 244160
EQS News ID: 1634691
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1634691&application_name=news
(END) Dow Jones Newswires
May 16, 2023 11:36 ET (15:36 GMT)
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Dec 2024 to Jan 2025
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Jan 2024 to Jan 2025
